HAEMONETICS CORP — Director's Dealing 2011

Oct 26, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2011-10-25

Reporting Person: CONCANNON BRIAN (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-10-24	Common Stock	D	143.0	$60.41	Disposed	37803.0	Direct
2011-10-25	Common Stock	D	115.0	$61.03	Disposed	37688.0	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$22.635	2013-09-15	Common Stock (97000.0)	97000.0	Direct
Non-Qualified Stock Option (right to buy)	$26.105	2014-05-05	Common Stock (15000.0)	15000.0	Direct
Non-Qualified Stock Option (right to buy)	$41.15	2012-07-27	Common Stock (14000.0)	14000.0	Direct
Non-Qualified Stock Option (right to buy)	$51.07	2014-10-24	Common Stock (22890.0)	22890.0	Direct
Non-Qualified Stock Option (right to buy)	$52.76	2013-05-05	Common Stock (16644.0)	16644.0	Direct
Non-Qualified Stock Option (right to buy)	$52.94	2016-10-27	Common Stock (79675.0)	79675.0	Direct
Non-Qualified Stock Option (right to buy)	$54.55	2015-10-22	Common Stock (28588.0)	28588.0	Direct
Non-Qualified Stock Option (right to buy)	$54.99	2017-10-27	Common Stock (118375.0)	118375.0	Direct
Non-Qualified Stock Option (right to buy)	$55.37	2016-04-02	Common Stock (32845.0)	32845.0	Direct

Footnotes

F1: Pursuant to a 10b5-1 Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.